Floatz logo

Giapreza

Cirrhosis

The Cleveland ClinicPhase 4 / ApprovedActive
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
73/ 100

Competitive context

142 Active assets in the Cirrhosis cohort.

Asset / SponsorPhaseRating
PARITAPREVIR
AbbVie
Phase 3A
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE)
General Hospital of Shenyang Military Region
Phase 4BBB
Tolvaptan
Institute of Liver and Biliary Sciences, India
Phase 4BBB
CHOLYL-LYSL-FLUORESCEIN
Norgine
Phase 3BBB
Ribavirin
Peking University People's Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

Giapreza is also rated in:

disease related to solid organ transplantationDormant
BBB
Indicative ·
72 / 100
View asset →
acute kidney injuryDormant
BB
Indicative ·
70 / 100
View asset →
chronic liver failureDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →